Summary: Papillary renal cell carcinoma (pRCC) accounts for about 10% of renal parenchymal tumors. There are two pRCC subtypes reported in several studies, but so far limited molecular evidence to validate this pRCC subtyping in daily routine.
Romania, Cyprus, and Portugal [4] . In 2008, decreased or stabilized incidence in northern Europe countries occurred, particularly in Sweden, and generally increased (except for women in the early 2000s) in Eastern Europe [5] .
The mortality rates from kidney cancer in European Union (EU) peaked at 4.8/100 000 in [1990] [1991] [1992] [1993] [1994] , and declined to 4.1 (−13%) in 2000-2004 [5] . In women in the EU, the corresponding values were 2.1 and 1.8 [5] . In Portugal mortality rates in women declined (−14%) during 1990-2004 [5] .
Papillary RCC (pRCC) comprises ~ 6-18% of kidney tumors in reported series [6] . It is the most common histologic subtype observed in pediatric RCC and it was reported in 18 % of dialysis patients with less than 10 years of treatment [3, 7] . Atypical cysts with extensive papillary hyperplasia are often the precursors of papillary renal adenoma and cancer in these patients [8] . In children it may arise in the setting of pre-existing neoplasm, including Wilms tumor, metanephric adenoma, and metanephric adenofibroma [9] . Approximately 20% of pRCC are discovered as incidental findings [6] .
Vikram et al. reported that the range of age is in the third to eighth decades, and male-tofemale ratio from 2:1 to 3.9:1 [2]. There are no reports on specific symptoms and signs of pRCC. (with jaw tumor) HRPT2. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In 1994 hereditary papillary renal cancer (HPRC) was reported as a rare autosomal dominant inherited syndrome with very high penetrance (30 families described so far), meaning that there is a high probability of a person developing pRCC by age 80 [16-18, 20, 29] . An early onset-form has been recently reported in which the disease appears in the second and third decade [29] . Diagnosis of this condition is based on the detection of germline mutation of the c-MET gene;
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c-MET mutations were reported to play a role in 13% of patients with pRCC and no family history of renal tumors [15, 16, 19, 30] (Table 1) . Mutations of c-MET were also reported in a subset of tumors from patients with sporadic type 1 pRCC [31] .
Hereditary leiomyomatosis RCC (HLRCC) mean age is 36-39 years, although the youngest age at diagnosis of pRCC in a fumarate hydratase (FH) gene mutation carrier was reported in a 11-year-old patient [23, 24] . Among 89 cases reported in the literature, six (7%) were found in individuals younger than 20 years [25] . Two distinct FH mutations occurring in heterozygote (2bpdel, codon 181 and R300X) were reported in HLRCC families affected by renal cancer and uterine leiomyosarcoma [21] . The renal tumors associated to HLRCC tend to be hypovascular, solitary, and may metastasize early [17] . Ultrastructure [35] . Type 1 pRCC: many glycogen granules, many secondary lysosomes containing lipid vacuoles, and few rough endoplasmic reticulum.
. Type 2 pRCC: many mitochondria, few lipid vacuoles, and many smooth endoplasmic reticulum.
In 1997, two consensus conferences, in Heidelberg, Germany, and Rochester, Minnesota, recognized the existence of benign papillary neoplasms of the renal tubular epithelium that are incidental findings, are much more common than clinically recognized pRCC [35] . At the Rochester conference it was recognized that there are no reliable histological differences between these small tumors and many clinically detected pRCC, and renal papillary adenoma was defined on the basis of size, less than 5mm, whereas larger tumors were classified as pRCC [35] .
Classically, tumors have been classified as pRCC if papillary structures comprise at least 50% but a variety of other architectural patterns such as tubular, trabecular and solid were reported [15, 37] . Kovacs et al. suggested that more than 75% of the tumor being composed of papillary structures may be a better criteria for discriminating pRCCs from nonpapillary RCCs showing 3p
deletions [37] . The presence of solid variants of pRCC that are composed of poorly formed papillae were reported and this group comprises at most <3% of all pRCC [15] .
The morphologic classification of pRCC into type 1 and 2 tumors has been supported by several histologic studies, although there is relatively limited molecular evidence to substantiate this subtyping [38] . Type 2 pRCC is composed of at least two genetically distinct subtypes: one subtype (type 2A) resembles type 1 in terms of indolent tumor behavior, excellent survival, low tumor grade, similar expression profiles, immunoreactivity, and inferred cytogenetic profiles; the other subtype (type 2B) is an highly metastatic, aggressive cancer that is molecularly distinct from type 1 or 2A tumors [38] . Other immunohistochemical markers are expressed in pRCC but with less diagnosis impact than the immunohistochemical markers described on Table 3 .
Immunohistochemistry features
Cell cycle fraction (Ki-67 index) and cell cycle rate (AgNOR score) are different when comparing the two histologic types of pRCC: both mean AgNOR score and mean Ki-67 index seem to be significantly higher in type 2 tumors [57] . [58] . Cells with moderate to scant cytoplasm . Small and uniform nuclei, often with prominent nuclear groves . Single and small nucleoli with mild to moderate hipercromasia and mild pleomorphism . Low to moderate nuclear/cytoplasm ratio . Foamy macrophages in the background . Intracellular hemosiderin . Psammoma bodies within the papillae, and in the background.
Fine needle aspiration (FNA)
Cytological features that are highly sensitive for the diagnosis of pRCC include intracytoplasmic hemosiderin and foamy macrophages [58] . These findings, in combination with the presence of papillae, nuclear grooves, inconspicuous nucleoli, increased nuclear to cytoplasmic ratio, are helpful in the FNA diagnosis of pRCC [58] .
The presence of unusually numerous balls or three-dimensional clusters of cells with smooth borders represent the fragmented tips of the papillae [58] . This appearance may be an artifact, but is reproducible and may be useful for the diagnosis [58] .
Flow cytometry features
DNA aneuploidy was reported in 50% pRCC [15] . According to del Vecchio et al. diploid
and aneuploid patterns occur in 35% and 65% of tumors, respectively [59] ; a strong correlation between nuclear grade and stage, as well as between nuclear grade/stage and ploidy pattern; and a strong correlation between nuclear grade/stage, ploidy pattern and clinical outcome.
Chromosomal analysis
Hierarchical clustering suggested two cytogenetic patterns that were reported to be common but not restricted to type 2 pRCC; one was characterized by combined high-level gains (ratios ≥2) of various chromosomes, including those commonly gained as primary and secondary aberrations, and another by weakly correlated patterns of less common secondary chromosomal losses (ratios ≤1), including losses at 17p; there are increased numbers of chromosomal abnormalities in type 2 tumors [60] (Table 4) . [38] . The considerable variation in the proportion of type 1 and 2 pRCC highlights the importance of assigning tumors into their correct subtype, according to established criteria [6] .
Al-Saleem et al. reported a rare example of oncocytoma to pRCC progression with losses of chromosomes Y and 1, a common feature of oncocytoma, and a gain of chromosome 7, a feature of pRCC [80] .
So far there are few reports of epigenetic alterations in pRCC. In one study of 61 tumors, TU3A (the candidate tumor suppressor gene -located at 3p21.1) was methylated in 42% of clearcell RCC and 25% of pRCC [81, 82] . The FHIT gene encompasses the common fragile site FRA3B at 3p14, involved in purine metabolism. FHIT promoter methylation is common (52 to 53%) in both clear-cell RCC and pRCC [81] . SPINT2 (serine peptidase inhibitor) which encodes a secreted inhibitor of c-MET activity (activating mutations in the c-MET proto-oncogene associate with familial pRCC, although somatic mutations are infrequent in sporadic pRCC) [81] . Table 5 summarizes pRCC treatment.
Treatment
Papillary RCC treatment . Surgery
Radical nephrectomy and lymph node dissection can cure early stage pRCC; relapses occur in 20-30% patients.
. Systemic therapy
Renal tumors are highly resistant to both chemotherapy and radiotherapy.
Sunitinib (tyrosine kinase inhibitor), sorafenib (tyrosine kinase inhibitor) and temsirolimus (mTOR inhibitor) approved by US Food and Drug Administration.
Foretinib-tyrosine kinase inhibitor as well as of VEGR2 -ongoing Phase II clinical trial. Metastatic pRCC is characterized by resistance to systemic therapy and by poor survival [83] . The use of sunitinib and sorafenib, recently approved for advanced RCC, as well as other VEGF-based therapies warrant study in the clinical trials for patients with metastatic pRCC [83] .
Prospective efforts to characterize the activity of sunitinib in metastatic pRCC yielded disappointing response rates [84] . A recent study of 41 patients with metastatic pRCC receiving sunitinib (13 patients) or sorafenib treatment (28 patients) reported a low overall partial response rate of 4.8% (2 of 41 patients) [85] . Both responders were treated with sunitinib and had response durations of 8 and 12 months [85] . The Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program allowed patients in the United States and Canada with metastatic RCC to receive treatment with sorafenib prior to its regulatory approval [86] . This non-randomized, open-label program treated 158 with pRCC out of 1891 patients [86] . Of the 107 evaluable subjects with pRCC, 90 (84%) had a measurable response to treatment with 3 partial responders and 87 with stable disease for at least 8 weeks, while 17 (16%) patients developed early progression on treatment [86] .
Treatment specific to the c-MET mutation associated with pRCC remains to be identified [83] . 17AAG, which acts by inhibiting heat shock protein and affects c-MET activation, achieved responses in a Phase II trial limited to pRCC patients [83] . Preclinical data, studying a monoclonal antibody to the c-MET ligand, hepatocyte growth factor, reported antitumor activity, which could offer a future novel treatment for patients with c-MET-dependent tumors [83] .
Hereditary papillary renal tumor tends to be occult and, if not detected and treated, can spread to other organs [29] . Parenchymal sparing surgery (partial nephrectomy) is recommended when the largest renal tumor approaches 3 cm in size [29] . Patients whose tumors are < 3 cm are generally managed with observation [29] . The goal of management is to maintain the patient's renal function while minimizing the risk for metastasis [29] .
Potential areas of systematic therapy for Hereditary Leiomyomatosis RCC will likely be designed to prevent increased HIF (Hypoxia induced factor) levels or target the transcription products of VHL-independent HIF accumulation, such as VEGF (Vascular endothelial growth factor) and TGF-α (Tumor growth factor alpha)/EGFR (Epidermal growth factor receptor) [16] .
One attempt to block the downstream effectors of FH inactivation is through the use of erlotinib, an oral EGFR tyrosine kinase inhibitor (TKI) [16] . A multicenter phase II trial with this agent in patients with locally advanced and metastatic pRCC reported an overall RECIST (Response evaluation criteria in solid tumors) response rate of 11% with an additional 24 patients (53%) experiencing stable disease [16] . Combination therapy with an mTOR inhibitor or VEGF pathway antagonist may potentiate the single agent activity of erlotinib [16] . A phase II trial of erlotinib (EGFR TKI) in combination with bevacizumab (monoclonal antibody against VEGF) is currently underway and is one of the trials designed to evaluate this strategy [16] .
Rebecca Lim et al. reported a case of spontaneous regression of histologically confirmed metastatic type 2 pRCC in the absence of intervening systemic therapy or surgery [87] . Table 6 summarizes pRCC prognostic factors.
Prognosis
Predictors
TNM staging system
The predictive value of the 2010 TNM regarding CSS of pRCC is not superior when compared to the 2002 TNM.
Nuclear grade
Significant differences for CSS of pT1b vs. pT2a and pT3b vs. pT3c in pRCC.
Histological subtype
Papillary histological subtype associates with good prognosis: low stage and grade, small tumor size and high % of CSS.
Type 2 is usually larger, advanced and less differentiated and displays more frequently necrosis and lymphovascular invasion compare to type 1.
Type 2 pRCC can present extensive nodal metastasis.
Tumor extension
The inferior vena cava, the renal vein, or its branches (stage T3b and T3c) occurs in 8.2%. Spread to mediastinal lymph nodes and supraclavicular lymph nodes are not unusual; such spread is considered to represent distant metastases and classified as M1
disease. Nodal involvement is not necessarily associated with worst prognosis.
Visceral metastases in 5.7%-11%, including lung, bone and brain, and low median survival (9.1 months).
Tumor necrosis
Controversial parameter as negative predictor for metastasis-free and overall survival.
FN1
Increased FN1 mRNA expression seems to correlate to aggressive behavior.
EGF-R
Intermediate/strong EGF-R expression seems to associate to higher tumor grade, distant metastasis, and worst long-term survival.
Claudin-1
Loss of claudin-1 expression occurs in aggressive tumors and associates to shortened disease-specific survival
IMP3
IMP3 expression may predict tumor metastasis in patients with localized disease.
Chromosomal abnormalities
Losses of 8p, 9p, and 11q associate with higher T-stage and higher clinical stage, loss of 8p with positive M-stage, and loss of 9p and gain of 3q with positive N-stage.
Polysomy 7 associates with higher nuclear grade and higher pathological stage. Two large pediatric series report the outcome of 32 patients with pRCC [9] . 75 % (24/32) presented with disease limited to the kidney, and 22 of the 24 were free of disease; death from disease occurred in one T2N0MX tumor and the other died from other causes [9] . Of the remaining eight patients with higher stage disease, three (T4N0MX, T3N1M0,T2,N2,M0) died of their disease [9] .
Future Perspectives
Papillary RCC is the second most common renal cell carcinoma. Regrettably pRCC is usually asymptomatic or without specific symptoms and signs, and approximately 20% of pRCC are incidental findings. There are no specific tumor markers available for diagnostic, prognostic or predictive purposes. Papillary RCC diagnosis, prognosis and treatment are based on histopathologic features but their subtyping seems unsatisfactory. Molecular profiling is an emerging promising tool for new biomarker identification that may provide a better understanding of pRCC pathogenesis and eventually improve the accuracy of predicting prognosis and treatment of patients.
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